We identified key epithelial–immune interactions in high EGFR expressing tumours such as LGALS3–LAG3, PLAU–PLAUR, MDK–(ITGA4+ITGB1) which can be therapeutically targeted with available inhibitors such as relatlimumab,7 upamostat8 and natalizumab9 alongside currently prescribed anti‐EGFR cetuximab10 to increase immune infiltration within tumour for potential prognostic benefit. Here, MDK is linked to neoplasm.